Synthetic immune niches for cancer immunotherapy

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Crit Rev Oncol Hematol.

Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, Scartozzi M, Saba L

doi: 10.1016/

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

Immunotherapy

Immunotherapy in Gastrointestinal Cancers

Biomed Res Int.

Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S

doi: 10.1155/2017/4346576.

ImmunotherapyT Cells

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

J Autoimmun.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P

doi: 10.1016/j.jaut.2019.102310.

Melanoma and Skin CancerImmunotherapy

Identification of essential genes for cancer immunotherapy

Nature.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP

doi: 10.1038/nature23477.

Immunotherapy

Novel immunotherapy strategies for hepatobiliary cancers

Immunotherapy.

DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ

doi: 10.2217/imt-2018-0024.

Immunotherapy

Recent progress in therapeutic antibodies for cancer immunotherapy

doi: 10.1016/j.cbpa.2018.05.006.

RECOMMENDED

Immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

doi: smw.2019.14697.

Immunotherapy

Is autoimmunity the Achilles' heel of cancer immunotherapy?

Nat Med.

June CH, Warshauer JT, Bluestone JA

doi: 10.1038/nm.4321.

Related content

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Immunotherapy in Gastrointestinal Cancers

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

Identification of essential genes for cancer immunotherapy

Novel immunotherapy strategies for hepatobiliary cancers

Recent progress in therapeutic antibodies for cancer immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

Is autoimmunity the Achilles' heel of cancer immunotherapy?